Baker Bros. Invests $33M in Replimune Pre-Funded Warrants at $12.06
REPL has more than doubled off its 52-week low of $1.5.
Summary
Baker Bros. entities bought $33.0 million of pre-funded warrants in Replimune's public offering, a significant insider commitment following FDA approval of TUDRIQEV.
Updates
· SEC SCHEDULE 13D/A — Baker Bros. reported beneficial ownership of 11,075,336 shares, or 11.8% of Replimune, after the offering closed August 11, 2026.
Key Events · Ownership and Investor Activity · REPL
-
$33M Insider Warrant Purchase
Baker Bros. Advisors and affiliated funds acquired 2,736,340 pre-funded warrants at $12.06 each, totaling $33.0 million, in the underwritten offering that closed August 11, 2026.
-
Effective Equity Commitment
The warrants have a nominal exercise price of $0.0001 and no expiration, making them economically equivalent to common stock at a $12.06 entry price — a direct $33M bet on Replimune's post-approval future.
-
Post-Approval Conviction Signal
The purchase comes four days after FDA accelerated approval of TUDRIQEV (RP1) for advanced melanoma, and one day after the company priced a $150M offering — Baker Bros. is doubling down despite near-term dilution and cash runway concerns.
-
Director/10% Owner Alignment
Baker Bros. already had board representation and a >10% stake; this purchase reinforces their long-term commitment and aligns their interests with shareholders as the company transitions to commercial stage.
Analysis · REPL · Life Sciences
Baker Bros. Advisors, a long-time major shareholder and board representative, purchased $33.0 million of pre-funded warrants in Replimune's just-closed public offering. The warrants are exercisable at $0.0001 per share, effectively a direct equity commitment at $12.06 per share — a vote of confidence from a sophisticated life-sciences investor just days after the company's first FDA approval. The purchase represents roughly 2.9% of the company's market cap and signals conviction in the commercial launch of TUDRIQEV, despite the recent going-concern warning and dilutive offering.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REPL was trading at $13.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.50 to $14.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.